{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:20:54Z","timestamp":1785489654206,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04633-w","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:08:21Z","timestamp":1767632901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cAntimicrobial susceptibility of carbapenem-resistant Acinetobacter baumannii against tetracycline, doxycycline, tigecycline, minocycline and colistin: experience from a tertiary care hospital in Karachi\u201d"],"prefix":"10.1186","volume":"26","author":[{"given":"Momina","family":"Ahsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareeha","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moiz Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Khursheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"1","key":"4633_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.55519\/JAMC-01-9105","volume":"34","author":"F Jabeen","year":"2022","unstructured":"Jabeen F, Khan Z, Sohail M, Tahir A, Tipu I, Murtaza Saleem HG. Antibiotic Resistance Pattern Of Acinetobacter Baumannii Isolated From Bacteremia Patients In Pakistan. J Ayub Med Coll Abbottabad. 2022;34(1):95\u2013100 Available from. https:\/\/doi.org\/10.55519\/JAMC-01-9105.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"4633_CR2","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","volume":"6(Suppl 1)","author":"AC Gales","year":"2019","unstructured":"Gales AC,Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. Antimicrobial susceptibility of Acinetobacter calcoaceticus\u2013Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: Results from the SENTRY Antimicrobial Surveillance Program (1997\u20132016). Open Forum Infect Dis. 2019;6(Suppl 1): S34\u201346. Available from. https:\/\/doi.org\/10.1093\/ofid\/ofy293.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"4633_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1017\/S0950268807009478","volume":"136","author":"M Falagas","year":"2008","unstructured":"Falagas M, Karveli E, Siempos I, Vardakas K. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol and Infect. 2008;136(8):1009-19. Available from. https:\/\/doi.org\/10.1017\/S0950268807009478.","journal-title":"Epidemiol and Infect"},{"key":"4633_CR4","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.2147\/idr.s469244","volume":"17","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang J, Gu Y, Wang L, Hu J. Nosocomial. Healthcare-Associated, and Community Acquired Acinetobacter baumannii in China: Clinical Characteristics, Antimicrobial Resistance Patterns and Risk Factors Associated with Carbapenem Resistance. Infect Drug Resist. 2024;17:4089\u201399. Available from. https:\/\/doi.org\/10.2147\/idr.s469244.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"4633_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/antibiotics9030119","volume":"9","author":"CA Moubareck","year":"2020","unstructured":"Moubareck CA, Halat DH. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9(3):119. Available from. https:\/\/doi.org\/10.3390\/antibiotics9030119.","journal-title":"Antibiotics"},{"issue":"1","key":"4633_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-018-0301-x","volume":"18","author":"ME Ibrahim","year":"2019","unstructured":"Ibrahim ME. Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance. Ann Clin Microbiol Antimicrob. 2019;18(1):1. Available from. https:\/\/doi.org\/10.1186\/s12941-018-0301-x.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"6","key":"4633_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/1348-0421.12887","volume":"65","author":"Y Akeda","year":"2021","unstructured":"Akeda Y. Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast Asia. Microbiol Immunol. 2021;65(6):229\u201337. Available from: https:\/\/doi.org\/10.1111\/1348-0421.12887.","journal-title":"Microbiol Immunol"},{"issue":"1","key":"4633_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12941-019-0344-7","volume":"19","author":"NKF Karah","year":"2020","unstructured":"Karah NKF, Wai SN, Uhlin BE, Ahmad I. Molecular epidemiology and antimicrobial resistance features of Acinetobacter baumannii clinical isolates from Pakistan. Ann Clin Microbiol Antimicrob. 2020;19(1):2. Available from. https:\/\/doi.org\/10.1186\/s12941-019-0344-7.","journal-title":"Clin Microbiol Antimicrob"},{"issue":"8","key":"4633_CR9","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/529198","volume":"46","author":"GM Eliopoulos","year":"2008","unstructured":"Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254\u201363. Available from: https:\/\/doi.org\/10.1086\/529198.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4633_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1128\/jcm.01588-06","volume":"45","author":"RN Jones","year":"2007","unstructured":"Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007;45(1):227\u2009\u2013\u200930. Available from. https:\/\/doi.org\/10.1128\/jcm.01588-06.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"4633_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0974-777x.68538","volume":"2","author":"V Manchanda","year":"2010","unstructured":"Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291\u2013304. Available from: https:\/\/doi.org\/10.4103\/0974-777x.68538.","journal-title":"J Glob Infect Dis"},{"key":"4633_CR12","doi-asserted-by":"publisher","unstructured":"Gorgun S, Guzel M, Gunal O, K\u0131l\u0131c SS. The Efficiency of Colistin, Minocycline, Tigecycline, and Doxycycline against multidrug-resistant Acinetobacter strains. Ann Clin Anal Med. 2021;12(02). Available from. https:\/\/doi.org\/10.4328\/acam.20207.","DOI":"10.4328\/acam.20207"},{"issue":"1","key":"4633_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/ipc.0b013e318159d595","volume":"16","author":"ME Griffith","year":"2008","unstructured":"Griffith ME, Yun HC, Horvath LL, Murray CK. Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Infect Dis Clin Pract. 2008;16(1):16\u2009\u2013\u20099. Available from. https:\/\/doi.org\/10.1097\/ipc.0b013e318159d595.","journal-title":"Infect Dis Clin Pract"},{"issue":"3","key":"4633_CR14","doi-asserted-by":"publisher","first-page":"e0150642","DOI":"10.1371\/journal.pone.0150642","volume":"11","author":"W-Y Kim","year":"2016","unstructured":"Kim W-Y, Moon J-Y, Huh JW, Choi S-H, Lim C-M, Koh Y, et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One. 2016;11(3):e0150642. Available from. https:\/\/doi.org\/10.1371\/journal.pone.0150642.","journal-title":"PLoS One"},{"issue":"15","key":"4633_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-016-0636-6","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL, Scott LJ. Intravenous Minocycline: A Review in Acinetobacter Infections. Drugs. 2016;76(15):1467\u201376. Available from: https:\/\/doi.org\/10.1007\/s40265-016-0636-6.","journal-title":"Drugs"},{"issue":"5","key":"4633_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","volume":"45","author":"ME Falagas","year":"2015","unstructured":"Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2015;45(5):455\u201360. Available from: https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.031.","journal-title":"Int J Antimicrob Agents"},{"key":"4633_CR17","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024;(ciae403) Available from: https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"4633_CR18","doi-asserted-by":"publisher","first-page":"S663","DOI":"10.51253\/pafmj.v72isuppl-3.9579","volume":"72(SUPPL-3)","author":"M Fayyaz","year":"2022","unstructured":"Fayyaz M, Khalil H, Mirza IA, Meral U, Zafar H, Hussain W. In Vitro Efficacy of Tetracyclines Against Multi Drug Resistant Acinetobacter Baumannii Amongst Intensive Care Patients. Pak Armed Forces Med J. 2022;72(SUPPL-3):S663-67. Available from. https:\/\/doi.org\/10.51253\/pafmj.v72isuppl-3.9579.","journal-title":"Pak Armed Forces Med J"},{"issue":"7","key":"4633_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7754\/clin.lab.2014.141116","volume":"61","author":"FK Cakirlar","year":"2015","unstructured":"Cakirlar FK, Ciftci IH, Gonullu N. OXA-type carbapenemases and susceptibility of colistin and tigecycline among carbapenem-resistant Acinetobacter baumannii isolates from patients with bacteremia in Turkey. Clin Lab. 2015;61(7):741-7. Available from. https:\/\/doi.org\/10.7754\/clin.lab.2014.141116.","journal-title":"Clin Lab"},{"key":"4633_CR20","doi-asserted-by":"publisher","unstructured":"Han R, Ding L, Yang Y, Guo Y, Yin D, Wu S, et al. In vitro activity of KBP-7072 against 536 Acinetobacter baumannii complex isolates collected in China. Microbiol Spectr. 2022;10(1). Available from: https:\/\/doi.org\/10.1128\/spectrum.01471-21.","DOI":"10.1128\/spectrum.01471-21"},{"key":"4633_CR21","unstructured":"Clinical & Laboratory Standards Institute M100. Ed34 [cited 2025 Mar 3]. Available from: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"4633_CR22","volume-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: WHO; 2024."},{"issue":"5","key":"4633_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.12669\/pjms.295.3695","volume":"29","author":"S Begum","year":"2013","unstructured":"Begum S, Hasan F, Hussain S, Shah AA. Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pak J Med Sci Q. 2013;29(5):1253 Available from. https:\/\/doi.org\/10.12669\/pjms.295.3695.","journal-title":"Pakistan. Pak J Med Sci Q"},{"issue":"2","key":"4633_CR24","doi-asserted-by":"publisher","first-page":"106707","DOI":"10.1016\/j.ijantimicag.2022.106707","volume":"61","author":"C-H Chen","year":"2023","unstructured":"Chen C-H, Wu P-H, Lu M-C, Ho M-W, Hsueh P-R. Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2023;61(2):106707. Available from: https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106707.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"4633_CR25","doi-asserted-by":"publisher","first-page":"e61785","DOI":"10.7759\/cureus.61785","volume":"16","author":"V Punithavathi","year":"2024","unstructured":"Punithavathi V, Ramalingam AJ, Chitralekha S. An Ancient Drug for a Modern Era: Minocycline for the Treatment of Multi-Drug-Resistant Acinetobacter baumannii. Cureus. 2024;16(6):e61785. Available from: https:\/\/doi.org\/10.7759\/cureus.61785.","journal-title":"Cureus"},{"key":"4633_CR26","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1590\/S1678-9946202062088","volume":"62","author":"M Beheshti","year":"2020","unstructured":"Beheshti M, Ardebili A, Beheshti F, Lari AR, Siyadatpanah A, Pournajaf A, et al. Tetracycline resistance mediated by tet efflux pumps in clinical isolates of Acinetobacter baumannii. Rev Inst Med Trop Sao Paulo. 2020;62:e88. Available from: https:\/\/doi.org\/10.1590\/S1678-9946202062088.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"5","key":"4633_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.26689\/jcnr.v8i5.7305","volume":"8","author":"H Wang","year":"2024","unstructured":"Wang H. Clinical Efficacy and Safety Analysis of Tigecycline in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Combined with Multidrug-Resistant Acinetobacter baumannii Infection. Clin Nurs Res. 2024;8(5):194\u201399. Available from: https:\/\/doi.org\/10.26689\/jcnr.v8i5.7305.","journal-title":"Clin Nurs Res"},{"key":"4633_CR28","doi-asserted-by":"publisher","first-page":"1395260","DOI":"10.3389\/fcimb.2024.1395260","volume":"14","author":"S Zhang","year":"2024","unstructured":"Zhang S, Di L, Qi Y, Qian X, Wang S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 2024;14:1395260 Available from: https:\/\/doi.org\/10.3389\/fcimb.2024.1395260.","journal-title":"Front Cell Infect Microbiol"},{"key":"4633_CR29","doi-asserted-by":"publisher","unstructured":"Charles R, Adhikari SD, Mittal A, Chaudhuri S, et al. Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports. Infez Med. 2022;30(4) Available from: https:\/\/doi.org\/10.53854\/liim-3004-5.","DOI":"10.53854\/liim-3004-5"},{"issue":"1","key":"4633_CR30","doi-asserted-by":"publisher","first-page":"17091","DOI":"10.1038\/srep17091","volume":"5","author":"Z Chen","year":"2015","unstructured":"Chen Z, Chen Y, Fang Y, Wang X, Chen Y, Qi Q, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci rep. 2015;5(1):17091. Available from: https:\/\/doi.org\/10.1038\/srep17091.","journal-title":"Sci Rep"},{"issue":"3","key":"4633_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/antibiotics13030287","volume":"13","author":"W Katip","year":"2024","unstructured":"Katip W, Rayanakorn A, Sornsuvit C, Wientong P, Oberdorfer P, Taruangsri P, et al. High-loading-dose colistin with nebulized administration for carbapenem-resistant Acinetobacter baumannii pneumonia in critically ill patients: A retrospective cohort study. Antibiotics. 2024;13(3):287. Available from: https:\/\/doi.org\/10.3390\/antibiotics13030287.","journal-title":"Antibiotics"},{"issue":"6","key":"4633_CR32","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/pharmaceutics14061266","volume":"14","author":"W Katip","year":"2022","unstructured":"Katip W, Oberdorfer P, Kasatpibal N. Effectiveness and nephrotoxicity of loading dose colistin-meropenem versus loading dose colistin-imipenem in the treatment of carbapenem-resistant Acinetobacter baumannii infection. Pharmaceutics. 2022;14(6):1266. Available from. https:\/\/doi.org\/10.3390\/pharmaceutics14061266.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4633_CR33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/antibiotics12030516","volume":"12","author":"K Novovi\u0107","year":"2023","unstructured":"Novovi\u0107 K, Jov\u010di\u0107 B. Colistin resistance in Acinetobacter baumannii: molecular mechanisms and epidemiology. Antibiotics. 2023;12(3):516. Available from: https:\/\/doi.org\/10.3390\/antibiotics12030516.","journal-title":"Antibiotics"},{"issue":"1","key":"4633_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12879-025-10535-z","volume":"25","author":"N Khursheed","year":"2025","unstructured":"Khursheed N, Adnan F, Khan MA, Hatif R. Regional insights on the prevalence and antimicrobial susceptibility pattern of carbapenem and colistin-resistant gram-negative bacteria: an observational cross-sectional study from Karachi, Pakistan. BMC Infect Dis. 2025;25(1):186. Available from. https:\/\/doi.org\/10.1186\/s12879-025-10535-z.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04633-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:35:48Z","timestamp":1770831348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-025-04633-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4633"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04633-w","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the ethical principles of the Declaration of Helsinki and was approved by the Institutional Review Board (IHHN-IRB#1) of the Indus Hospital & Health Network with reference number (IHHN_IRB_2022_12_030). The requirement for informed consent was waived by the Institutional Review Board of the Indus Hospital and Health Network as the study involved minimal risk to participants and used anonymized data. Exemption was granted under the IRB clause which categorized the study as Secondary research for which consent is not required and involves the re-use of data and specimens that were or will be collected for non-research purposes or from research studies other than the proposed research study. The research materials typically will be publicly available materials, medical records, or existing repositories of clinical specimens. No contact between investigator and subject is allowed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}